MedTrace Logo

Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone

NCT06186141 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2025-08-27

No results posted yet for this study

Summary

POPCORN trial will compare the side effects and effectiveness of Morphine versus Oxycodone medication when prescribed for use as patient controlled analgesia (PCA) for pain relief for paediatric patients after-surgery. This trial is embedded into routine patient care using the hospital electronic medical record (EMR). Participants will be randomly assigned to either medication after they enrol in the study.

The main questions the POPCORN trial aims to answer are:

* 1\. Is there a difference in the usage of medication to treat nausea and vomiting for those who received oxycodone PCA versus morphine PCA for post-surgery pain relief?
* 2\. Is there a difference in side effects or pain relief needed between the two groups?

Study activities are as follows:

* Participants enrolled to study during their pre-operative consultation
* Participants are randomly assigned to morphine or oxycodone
* No further study-specific activities expected from participant after enrolment and randomisation
* Participant receives routine medical care as planned
* Clinicians record assessments as per routine care in electronic medical record (EMR)
* EMR data are extracted as trial data

Conditions

  • Patient-Controlled Analgesia

Interventions

DRUG

Morphine

Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

DRUG

Oxycodone

Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

Sponsors & Collaborators

  • Murdoch Childrens Research Institute

    lead OTHER

Principal Investigators

  • Sue May Koh · Murdoch Childrens Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2026-03-19
Completion
2027-03-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06186141 on ClinicalTrials.gov